Navigation Links
Regenicin, Inc., RGIN - Update
Date:2/2/2011

LITTLE FALLS, N.J., Feb. 2, 2011 /PRNewswire/ -- Regenicin, Inc.(OTC Bulletin Board: RGIN) a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs announced today that its Chairman and CEO, Randall McCoy is currently working with the board on a new Corporate incentive plan designed to encourage and reward the Company's officers, employees and consultants working with Regenicin.  As a show of his own commitment to the Company's growth and stability, Mr. McCoy has pledged to return 22 million of his own personal shares back into Treasury to support the program -- over 26% of the currently issued and outstanding shares of Regenicin."  

"I really believe in the future success of this Company and want all the people who are making it happen to benefit with me," said Mr. McCoy regarding the new incentive program.  "The best way I know how to do that without diluting the existing shareholders is to contribute my own shares to the program.  While this will reduce my holdings by nearly half, I believe it will enhance the overall value of the company creating a win, win for all the shareholders."

When asked about the recent adverse market activity, Mr. McCoy commented that it seemed particularly odd in view of the fact that the Company had incurred no fundamental change or negative developments. "The company remains on track and committed to its original business plan and creating value for the company and its shareholders."

About Regenicin

Regenicin, Inc. (www.regenicin.com) is a development stage biotechnology company. Regenicin is a publicly traded company, with headquarters in New Jersey. Additional information can be found in the company's filings with the Securities and Exchange Commission located at

SOURCE Regenicin, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioCells, Inc., a Cord Blood America Company, to Begin Storing Dental Pulp Stem Cells in Argentina
2. ISTO Technologies, Inc., Completes Enrollment in Phase I NuQu Clinical Trial
3. Johnson & Johnson Consumer Companies, Inc., Unveils CYTOMIMIC(TM) Technology at 68th Annual Meeting of the American Academy of Dermatology
4. LS9, Inc., U.C Berkeley, and JBEI Make Major Breakthrough in Cellulosic Fuels Production
5. BioSpec Global Solutions Inc., contracts with RMF Design & Manufacturing Inc., for production of the TOGs 3000 and 9000 units for U.S. market
6. Abbott to Acquire Evalve, Inc., a Leader in Minimally Invasive Cardiac Valve Repair Technology
7. ValGenesis, Inc., the Leading Provider of Validation Lifecycle Management Solutions to Regulated Life Science Companies, Today Announced Support for EMC Documentum v.6.5
8. BioStorage Technologies, Inc., Welcomes Catherine Michael as Global Head of Sample Management Operations
9. Sigma-Aldrich Acquires ChemNavigator, Inc., to Provide Researchers With Industry-Leading Chemical Compound Selection and Procurement Services
10. avVaa World Health Care Products, Inc. Signs Agreement with 3PL Worldwide, Inc., for Order Management & Fulfillment for avVaas Product
11. BioStorage Technologies, Inc., Appoints Jeff Goddard to Global Head of Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... (PRWEB) August 20, 2014 Not long ... E&L studies should be performed late in the development ... known. But current regulatory trends suggest that, like many ... the rise. In recent years, multiple drug sponsors have ... or address specific questions during phase I/II. It’s not ...
(Date:8/20/2014)... WriteResult®, a leading provider of Electronic Patient ... its myPROpad™ ePRO tablet with the addition of a ... most widely used and well-respected Patient Reported Outcome (PRO) ... is used during clinical trials and in other health ... used to demonstrate Health-Related Quality of Life outcomes (HRQoL) ...
(Date:8/19/2014)... 19, 2014 Shimadzu Scientific Instruments ... Prominence-i and Nexera-i, adding to the company’s extensive ... functionality, an intuitive operating environment, and full automation, ... efficient workflow for conventional to ultra-high-speed analysis. ... and intelligent design so users can begin building ...
(Date:8/19/2014)... Calif. (PRWEB) August 19, 2014 ... campaign to raise $200,000 to fund a corporate ... device. , This development is a critical ... model of care to the implementation of personalized ... method of practicing medicine. , Indiegogo contributions will ...
Breaking Biology Technology:Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2EQ-5D™ Assessment Now Available for iPad 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3
... 2011 Vaccinex, Inc. announced today that it has ... 1 clinical trial to assess the safety, tolerability, pharmacokinetics ... patients with advanced solid tumors. (Logo: ... antibody that blocks the activity of semaphorin 4D (SEMA4D). ...
... 4, 2011 Zeus, Inc., a global leader in ... expanded its capabilities and is now able to process ... Class 7 manufacturing environment. This expansion allows for the ... environment, resulting in compliance with stricter regulatory standards. ...
... announces that a new market research report is ... Opportunities in Biosimilar and Biobetter Drugs Markets ... Executive SummaryThe biosimilar and biobetter drugs market has ... following a series of changes in regulatory framework ...
Cached Biology Technology:Vaccinex, Inc. Initiates Clinical Trial of Novel Therapeutic Antibody in Cancer Patients With Advanced Solid Tumors 2Zeus Expands Class 7 Capabilities to Include the Processing of Advanced Polymers 2Reportlinker Adds Emerging Opportunities in Biosimilar and Biobetter Drugs Markets 2
(Date:8/20/2014)... suffered concussions ready to return to action? A new ... athletes who head back on the field with medical ... their abilities to simultaneously walk and do simple mental ... their balance and/or altered walking speed, was found in ... returned to activity in less than a month. Seven ...
(Date:8/20/2014)... pepper causes a burning spiciness that is irresistible to ... pepper,s effect are using their findings to develop a ... can be caused by inflammation or other problems. They ... tested in clinical trials, in ACS, Journal of ... that decades ago, scientists had pegged a compound called ...
(Date:8/20/2014)... could one day be made out of cocoa, rice ... reporting. The novel process they developed and their results, ... and plastic waste problems, appear in the ACS journal ... and colleagues at the Italian Institute of Technology point ... its production reached 288 million tons worldwide, but its ...
Breaking Biology News(10 mins):Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... Calif. The largest genome-wide association study ever ... cat allergies, has identified 16 new genetic associations ... collaboration between 23andMe, the leading personal genetics company, ... Children (ALSPAC), examined data for more than 53,000 ...
... the Denver Police Crime Lab and the University of Colorado, have ... leukocyte (white blood cell) and a cancer cell fuse to form ... ONE , may answer the question of how cancer cells travel ... tissues of the body the deadly process of metastasis. ...
... and medical students each received a one-year, $40,000 ... psoriatic arthritis. The National Psoriasis Foundation Amgen Medical ... scientists studying and treating psoriatic diseases by encouraging ... and psoriatic arthritis as physician researchers. The ...
Cached Biology News:23andMe and ALSPAC identify 16 new genetic associations for pollen, dust-mite and cat allergies 223andMe and ALSPAC identify 16 new genetic associations for pollen, dust-mite and cat allergies 3National Psoriasis Foundation awards 12 psoriasis and psoriatic arthritis research fellowships 2National Psoriasis Foundation awards 12 psoriasis and psoriatic arthritis research fellowships 3
... N,N- bis- (3-D-Gluconamidopropyl)deoxycholamide White solid. ... and CHAPSO. Has reduced electrostatic interactions that ... on DEAE-cellulose. Aggregation number: 8-16. Purity: ... 2 O. Aggregation number 8 - 16, ...
... White crystalline solid. HYGROSCOPIC. Water-soluble zwitterionic detergent ... 252005) but differing in the length of ... extraction of mycoplasma membrane antigens under mild ... TLC. Soluble in H 2 O. ...
Anti-Protein Kinase-A (PKA) Regulatory subunit IIB; rabbit host...
Identify and characterize Phosphoinositide (PI(3,4,5)P3) binding...
Biology Products: